Dr. Shah on the Curative Potential of CAR T-Cell Therapy in Myeloma

Video

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the curative potential of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the curative potential of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

CAR T-cell therapy has the potential to be effective in select patients with myeloma, but not all, says Shah. Myeloma is a notoriously difficult disease to eradicate completely, she adds, which lowers the likelihood of cure with CAR T-cell therapy. That is not to say that there will not be patients who will have long-term responses with the therapy, says Shah. The onus is on investigators to determine how much benefit is worth undergoing the therapy and its cost.

Everything that physicians now know about myeloma and treatment strategies are due to clinical trials, explains Shah. Clinical trials are a great way to achieve further advancement in the field. It is important to know that the standard of care is always given, regardless of which arm a patient is enrolled in, she adds.

Related Videos
Deepak L. Bhatt, MD, MPH, MBA
John A. Charlson, MD
Jeffrey Chamberlain, PhD
David Porter, MD
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Jonathan W. Weinsaft, MD
Omid Hamid, MD
Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital
Robert J. Hopkin, MD
Michael Kelly, PhD
© 2024 MJH Life Sciences

All rights reserved.